Discovery of 5,7-Dimethoxy-2-(3,4,5-trimethoxyphenoxy)-chromen-4-one with Lipid Lowering Effects in Hepatocytes

Discovery of 5,7-Dimethoxy-2-(3,4,5-trimethoxyphenoxy)-chromen-4-one with Lipid Lowering Effects in Hepatocytes

The population with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing. However, no medicine is indicated for treating these diseases clinically nowadays. Therefore, there is an urgent need to develop a new drug to overcome NAFLD and NASH. Capillarisin, a...

Full description

Bibliographic Details
Main Authors:	Yi-Han Chang, Chia-Hung Yen, Chih-Chung Lai, Hsuan-Yu Lai, Hsin-Yi Hung
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Pharmaceuticals
Subjects:	capillarisin 2-phenoxychromone NAFLD and NASH Huh7 cells lipid accumulation PGC1α
Online Access:	https://www.mdpi.com/1424-8247/15/4/449

Similar Items

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet
by: Suresh R. Giri, et al.
Published: (2023-01-01)

Modulation of Cyclins, p53 and Mitogen-Activated Protein Kinases Signaling in Breast Cancer Cell Lines by 4-(3,4,5-Trimethoxyphenoxy)benzoic Acid
by: Kuan-Han Lee, et al.
Published: (2014-01-01)

Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH
by: Laurianne Bonnet, et al.
Published: (2022-08-01)

Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
by: Mary Patricia Moore, et al.
Published: (2023-05-01)

NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular CarcinomaSummary
by: Yueqi Zhang, et al.
Published: (2024-01-01)

Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD
by: Katharina Schilcher, et al.
Published: (2023-08-01)

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
by: Wei-Qiang Leow, et al.
Published: (2020-08-01)

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
by: Benedetta Maria Motta, et al.
Published: (2023-11-01)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
by: Jian Huang, et al.
Published: (2023-04-01)

Renal resistive index in non-alcoholic fatty liver disease as an indicator of early renal affection
by: Hossam El-Din A. Mahmoud, et al.
Published: (2020-02-01)

Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot Study
by: Reda Albadawy, et al.
Published: (2021-09-01)

Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC
by: Yueqi Zhang, et al.
Published: (2021-05-01)

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4
by: Katharina John, et al.
Published: (2022-07-01)

Prolonged Lipid Accumulation in Cultured Primary Human Hepatocytes Rather Leads to ER Stress than Oxidative Stress
by: Christiane Rennert, et al.
Published: (2020-09-01)

Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Young-Su Yi
Published: (2024-03-01)

Lipid-Independent Regulation of PLIN5 via IL-6 through the JAK/STAT3 Axis in Hep3B Cells
by: Marinela Krizanac, et al.
Published: (2023-04-01)

MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression
by: Chiara Compagnoni, et al.
Published: (2023-05-01)

Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)
by: Jonas Wagner, et al.
Published: (2023-01-01)

(E)-3,4,5-Trimethoxy-N′-[(4-oxo-4H-chromen-3-yl)methylidene]benzohydrazide
by: Yoshinobu Ishikawa, et al.
Published: (2014-04-01)

Analysis of HBV Genomes Integrated into the Genomes of Human Hepatoma PLC/PRF/5 Cells by HBV Sequence Capture-Based Next-Generation Sequencing
by: Tomotaka Ishii, et al.
Published: (2020-06-01)

Potential Therapeutic Targets and Promising Agents for Combating NAFLD
by: Atsushi Umemura, et al.
Published: (2022-04-01)

From Liver Fat to Cancer: Perils of the Western Diet
by: Ju Youn Kim, et al.
Published: (2021-03-01)

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
by: Roberta Forlano, et al.
Published: (2022-07-01)

Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
by: Benoit Smeuninx, et al.
Published: (2020-06-01)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
by: Andrea Boccatonda, et al.
Published: (2023-03-01)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
by: Francesca Fianchi, et al.
Published: (2021-06-01)

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
by: Marija Branković, et al.
Published: (2022-05-01)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
by: Paola Dongiovanni, et al.
Published: (2021-10-01)

Associations between perfluoroalkyl substances and the severity of non-alcoholic fatty liver disease
by: Norma David, et al.
Published: (2023-10-01)

Surveillance for Hepatocellular Carcinoma in Patients with NASH
by: Philippe Kolly, et al.
Published: (2016-06-01)

Survey of non-alcoholic steatohepatitis in non-diabetic Haemodialysis patients in Beni-Suef Governorate
by: Ahmed Ibrahima, et al.
Published: (2022-10-01)

Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?
by: Angeliki Papachristodoulou, et al.
Published: (2021-06-01)

Deletion of Perilipin 5 Protects against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation
by: Anastasia Asimakopoulou, et al.
Published: (2020-05-01)

E4orf1 Prevents Progression of Fatty Liver Disease in Mice on High Fat Diet
by: Rownock Afruza, et al.
Published: (2022-08-01)

Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
by: Seyedeh Kosar Mahmoudi, et al.
Published: (2024-03-01)

Heat Shock Protein 60 Restricts Release of Mitochondrial dsRNA to Suppress Hepatic Inflammation and Ameliorate Non-Alcoholic Fatty Liver Disease in Mice
by: Ying-Hsien Huang, et al.
Published: (2022-01-01)

Development of a Hybrid Polymer-Based Microfluidic Platform for Culturing Hepatocytes towards Liver-on-a-Chip Applications
by: Gulsim Kulsharova, et al.
Published: (2021-09-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
by: Wesam Bahitham, et al.
Published: (2024-02-01)

Implementation of a randomized mobile-technology lifestyle program in individuals with nonalcoholic fatty liver disease
by: Monica A. Tincopa, et al.
Published: (2024-03-01)

Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
by: Feryal Savari, et al.
Published: (2024-04-01)